"Recently, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation. That may act as a severe headwind for Pfizer, whose coronavirus franchise - Paxlovid and Comirnaty - contributed $11.1 billion in combined revenue in 2024."
"The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of the 20th century saw Pfizer invent Viagra (erectile dysfunction), Zoloft (anti-depressant) and Lipitor (high cholesterol) treatments, catapulting the company to a market cap in the hundreds of billions."
Pfizer's stock has exhibited recent volatility, gaining 4.50% over the past month after a 6.50% decline the prior month, with a year-to-date loss of 7.59% and a one-year decline of 13.38%. The FDA will recommend COVID-19 vaccines only for seniors 65+ and people with certain medical conditions, reducing the eligible market for healthy adults and some children, which risks pressure on vaccine sales. Paxlovid and Comirnaty generated $11.1 billion in combined 2024 revenue. Pfizer forecasts 2025 revenues of $61–$64 billion and expects oncology and newly acquired drugs to offset waning COVID product sales. The company pays a 6.99% dividend yield.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]